Lidia Mondoc

Dr. Lidia Mondoc


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ACAlina Camelia Cătană
Alina Camelia Cătană
MVMaria-Gabriela Vladoiu
Maria-Gabriela Vladoiu
MSMariana Sandu
Mariana Sandu
AOAriela Olteanu
Ariela Olteanu
LMLiliana Mocanu
Liliana Mocanu
GMGeanina Mera
Geanina Mera
Acute lymphoblastic leukemia (ALL) is a malignant condition of lymphoid progenitor cells that primarily affects the pediatric population, but also adults. The 5-year survival rate is 90% in children and approximately 40% in adults, with survival increasing through the use of peripheral stem cell allotransplantation (SCT). The relapse rate after stem cell transplantation (SCT) in adult acute lymphoblastic leukemia (ALL) patients ranges from 35% to 45%, making relapse a major cause of death in this population. Background: We present an atypical case of late testicular involvement in ALL in a 50-year-old man diagnosed with ALL pro-T in remission post-chemotherapy (GMALL 2003 protocol) and allogeneic stem cell transplantation (alloSCT) from a related donor. Methods: This case describes a 50-year-old male with ALL pro-T who experienced three rare extramedullary relapses post-chemotherapy and alloSCT. Five years after remission, he had a unilateral testicular relapse confirmed by immunophenotyping of spermatic fluid. Results: Despite no bone marrow involvement, he was treated with chemotherapy, intrathecal therapy, and bilateral testicular radiotherapy. He later relapsed in the orbit, controlled by radiotherapy, followed by a third relapse in the heart and colon. Conclusions: This case highlights the unusual sites and consecutive nature of extramedullary relapses in adult ALL.

23 March 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
ACAlina Camelia Cătană
Alina Camelia Cătană
EBErzebeth Lazar Benedek
Erzebeth Lazar Benedek
SZSORIN IOAN ZAHARIE
SORIN IOAN ZAHARIE
LMLiliana Mocanu
Liliana Mocanu
GMGeanina Mera
Geanina Mera
Lidia MondocLidia Mondoc
Lidia Mondoc
Background and Clinical Significance: Mixed-phenotype acute leukemia (MPAL) is a rare hematologic malignancy characterized by the co-expression of myeloid and lymphoid markers and is associated with poor prognosis. Myeloid sarcoma (MS), particularly in the mediastinum, is an uncommon extramedullary manifestation and is rarely reported in association with MPAL. Case Presentation: We report a rare case of mediastinal MS with biphenotypic features and pericardial extension occurring concurrently with MPAL, highlighting diagnostic challenges, therapeutic strategies, and long-term outcomes. We describe the clinical course, diagnostic workup, treatment, and follow-up of a 21-year-old woman who presented with cardiac tamponade secondary to a mediastinal mass. Histopathology and immunophenotyping established the diagnosis of mediastinal MS associated with MPAL (B/myeloid, NOS). Management included surgical cytoreduction, intensive induction chemotherapy, and consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an unrelated donor. Fertility preservation with oocyte retrieval, in vitro fertilization (IVF), and embryo cryopreservation was performed prior to conditioning. A focused literature review of MPAL cases with extramedullary involvement was conducted. The patient achieved complete remission following induction therapy and underwent allo-HSCT. Despite the historically poor prognosis of mediastinal MS and MPAL, she remains in sustained complete remission 13 years after diagnosis. A literature review identified only eight reported cases of MPAL with extramedullary disease, with mediastinal involvement described in a single case and allo-HSCT performed in only two patients. Conclusions: This case illustrates a rare presentation of MPAL with mediastinal myeloid sarcoma and cardiac tamponade, demonstrating that aggressive multimodal therapy including allo-HSCT may achieve durable remission even in high-risk presentations. Early multidisciplinary management and consideration of fertility preservation are essential in young patients.

16 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ACAlina Camelia Cătană
Alina Camelia Cătană
Lidia MondocLidia Mondoc
Lidia Mondoc
MVMaria-Gabriela Vladoiu
Maria-Gabriela Vladoiu
ZVZsofia Varady
Zsofia Varady
CDCamelia Dobrea
Camelia Dobrea
MTMinodora Teodoru
Minodora Teodoru
Introduction: Chronic lymphocytic leukemia (CLL) is a common adult leukemia often treated with fludarabine, cyclophosphamide, and rituximab (FCR). While effective, FCR can lead to therapy-related myeloid neoplasms (t-MN), including aggressive therapy-related acute myeloid leukemia (t-AML). Stem cell transplantation offers the best chance for long-term remission in these cases. Here, we report a rare case of t-AML with plasmacytoid dendritic cells (pDC-AML) developing after FCR treatment for CLL that was successfully treated with haplotransplantation. Case Presentation: A 57-year-old woman with CLL-B was treated with six cycles of FCR, achieving a complete response. Six years later, at age 63, she developed t-AML with a rare morphophenotypic subtype: acute myelomonocytic leukemia with plasmacytoid dendritic cells (pDC-AML) and monosomy 8. Diagnostic challenges included distinguishing this subtype from blastic plasmacytoid dendritic cell neoplasm (BPDCN). She was treated with high-dose cytarabine followed by haploidentical stem cell transplantation from her son. Haploidentical transplantation was prioritized due to the urgent clinical need in a patient with high-risk acute leukemia (therapy-related leukemia secondary to prior chemoimmunotherapy and failure to achieve complete remission following the standard 3 + 7 induction protocol). In this critical setting, the patient’s son was immediately available as an HLA-haploidentical donor. Prior to the performance of the haploidentical stem cell transplant from her son, no HLA-matched unrelated donor (MUD) could be identified. Another viable alternative would have been the utilization of umbilical cord blood-derived stem cells harvested from the patient’s twin granddaughters. She was closely monitored post-transplant for potential complications, including graft-versus-host disease (GVHD), post-transplant lymphoproliferative disorder, and thyroid dysfunction, all of which were ruled out during follow-up. The patient remains in complete remission 15 years after her initial CLL diagnosis and 8 years after the t-AML diagnosis and haplotransplantation. Notably, no residual CLL clone was detected at the time of t-AML development, and a benign polyclonal lymphocytosis observed between 2018 and 2020 spontaneously resolved without intervention. Conclusions: This case illustrates the potential for long-term survival in high-risk patients with therapy-related AML developed after cytotoxic treatment for lymphoid malignancies. Haplotransplantation from a semi-identical Human Leukocyte Antigen (HLA) donor proved to be a viable and effective treatment option despite the patient’s age and dual hematologic malignancies.

4 October 2026 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
ACAlina Camelia Cătană
Alina Camelia Cătană
Victoria BirlutiuVictoria Birlutiu
Victoria Birlutiu
RCREMUS-CALIN CIPAIAN
REMUS-CALIN CIPAIAN
MPMonica Patran
Monica Patran
SMSandu Mariana
Sandu Mariana
Lidia MondocLidia Mondoc
Lidia Mondoc
Background: Mucormycosis is a rapidly progressive and often fatal invasive fungal infection requiring immediate suspicion-driven diagnosis and treatment, particularly in immunocompromised patients. We report the first documented case of rhino-sino-orbital mucormycosis in a patient with recurrent intrahepatic cholangiocarcinoma and summarize our single-centre experience with eight cases of mucormycosis in oncohematologic patients. Methods: A 50-year-old woman developed rhino-sino-orbital mucormycosis after multimodal treatment for recurrent cholangiocarcinoma. Because of high clinical suspicion, imaging was performed before microbiological confirmation and antifungal therapy was initiated immediately through multidisciplinary management. Results: The patient survived 16 years after the initial cancer diagnosis, seven years after recurrence, and two years following mucormycosis. Our institutional series included eight cases with rhino-sino-orbital, pulmonary, cutaneous, and urinary tract involvement, most diagnosed after 2020, highlighting heterogeneous presentations and breakthrough infection despite prior antifungal exposure. Clinical experience gained from these cases contributed to early recognition and successful management of the present patient. Conclusions: To our knowledge, this is the first reported case of mucormycosis in cholangiocarcinoma. These findings emphasize that mucormycosis should be considered a medical emergency in patients with hematologic malignancies or solid tumors, and antifungal therapy should be initiated based solely on clinical suspicion without waiting for microbiological confirmation, even in atypical presentations.

26 October 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
ACAlina Camelia Catana
Alina Camelia Catana
Corina PorrCorina Porr
Corina Porr
Lidia MondocLidia Mondoc
Lidia Mondoc
LMLiliana Mocanu
Liliana Mocanu
AOAriela Olteanu
Ariela Olteanu
Gabriela IancuGabriela Iancu
Gabriela Iancu
Background/Objectives: Systemic mastocytosis (SM) is a heterogeneous clonal mast-cell neoplasm requiring integrated clinical, biochemical, morphological, immunophenotypic, and molecular assessment. This study aimed to characterize the diagnostic and biological heterogeneity of SM across different disease phenotypes. Methods: We retrospectively reviewed six patients with SM diagnosed and managed between 2018 and 2022 at a single center. Clinical presentations, organ involvement, serum tryptase concentrations, bone marrow morphology, immunophenotypic and molecular findings, treatment, and outcomes were analyzed. Results: The cohort included four males and two females aged 16–86 years. Cutaneous manifestations occurred in five patients and frequently preceded diagnosis. All patients had bone marrow involvement, with variable mast-cell infiltration and aberrant CD25 and/or CD2 expression. Serum tryptase concentrations ranged from 15.8 to 348 μg/L. The highest concentration occurred in Patient 5, who had a FIP1L1::PDGFRA-positive myeloid/lymphoid neoplasm with eosinophilia and prominent systemic mast-cell involvement. In contrast, Patient 6, diagnosed with mast cell leukemia, had a tryptase concentration of 28.5 μg/L despite extensive marrow and peripheral blood involvement. KIT mutations were detected in five patients, while Patient 6 tested negative. Conclusions: This series highlights the marked clinical and biological heterogeneity of SM and the potential discordance between serum tryptase concentrations, mast-cell burden, molecular findings, and disease aggressiveness. Accurate diagnosis and disease characterization require an integrated multidisciplinary approach.